Benefit From tPA for Stroke Patients Receiving Antiplatelet Therapy
- Quantitative spectrophotometric assay of renal tissue plasminogen activator. Gilboa, Nisan; Erdman, Janice; Urizar, Rodrigo E. // Kidney International;Jul1982, Vol. 22 Issue 1, p80
Discusses the quantitative spectrophotometric assay of renal tissue plasminogen activator (TPA). Diluting kidney homogenate; Standard curve preparation using Lys-plasminogen; Linear relationship between tissue plasminogen activator and incubation time of the tissue.
- Alteplase (Cathflo Activase ). Middleton, Gena; Ruzevick, Bette; Lindemann, Karen // Clinical Journal of Oncology Nursing;Aug2004, Vol. 8 Issue 4, p417
Provides information on the human tissue plasminogen activator alteplase (Cathflo Activase) from Genentech Inc. Dosage; Efficacy; Indications.
- TPA. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p753
An abbreviation for "tissue-plasminogen activator" is presented.
- Hypointense Transcerebral Veins at T2*-Weighted MRI: A Marker of Hemorrhagic Transformation Risk in Patients Treated With Intravenous Tissue Plasminogen Activator. Marc Hermier // Journal of Cerebral Blood Flow & Metabolism;Nov2003, Vol. 23 Issue 11, p1362
SUMMARY: Prediction of hemorrhagic transformation (HT) in patients treated by intravenous recombinant tissue-type plasminogen activator (rt-PA) is a challenging issue in acute stroke management. HT may be correlated with severe hypoperfusion. Signal changes may be observed at...
- What if it's not safe to give tPA in your hospital? // ED Legal Letter;May2008, Vol. 19 Issue 5, p58
The article relates the things that a physician should consider before giving tissue plasminogen activator (tPA) to a stroke patient, according to Edward Jauch, assistant professor in the department of emergency medicine at University of Cincinnati. Physicians should consider first whether the...
- Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry. Matsuo, Ryu; Kamouchi, Masahiro; Fukuda, Haruhisa; Hata, Jun; Wakisaka, Yoshinobu; Kuroda, Junya; Ago, Tetsuro; Kitazono, Takanari // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1
Objectives: The benefit of intravenous recombinant tissue plasminogen activator (rt-PA) therapy for very old patients with acute ischemic stroke remains unclear. The aim of this study was to elucidate the efficacy and safety of intravenous rt-PA therapy for patients over 80 years old. Methods: ...
- The Pursuit of Excellence in Acute Stroke Care. Silver, Brian // Canadian Journal of Neurological Sciences;Nov2005, Vol. 32 Issue 4, p401
Focuses on the increasing percentage of patients receiving tissue plasminogen activator in Canada. Treatment of patients in remote areas through bypass and transfer protocols; Reduction of the symptomatic intracranial hemorrhage rates in spite of a protocol violation rate; Delivery of enhanced...
- TPA use for Stroke in the Registry of the Canadian Stroke Network. Nadeau, Janel 0.; Shi, Steven; Fang, Jiming; Kapral, Moira K.; Richards, Janice A.; Silver, Frank L.; Hill, Michael D. // Canadian Journal of Neurological Sciences;Nov2005, Vol. 32 Issue 4, p433
Investigates the use of thrombolytic therapy with recombinant tissue plasminogen activator for ischemic stroke patients in the Registry of the Canadian Stroke Network in Canada. Assessment of the percentage of the symptomatic intracerebral hemorrhage rate; Occurrence of protocol violations;...
- Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction. Bergstein, Jerry M.; Riley, Mark // Kidney International;Jan1989, Vol. 35 Issue 1, p14
To study the effect of tissue plasminogen activator (TPA) therapy on glomerular fibrin deposition in the generalized Shwartzman reaction, rabbits were given an intravenous injection of TPA immediately following or three, four, or five hours after the second injection of endotoxin. Animals were...